Sorafenib (BAY 43-9006, Nexavar, Bayer Pharmaceuticals Corporation & Onyx Pharmaceuticals) is an orally active, unselective, multikinase agent that inhibits C-Raf and B-Raf (mutant and wild type) along with a number of other cellular proteins involved in tumor neovascularization and tumor cell proliferation and survival, including VEGFR-2, VEGFR-3, Flt3, FGFR1, PDGFR-β, c-Kit and p38α [9]. The gene discussed is PDGFRB; the disease is neoplasm.